Sector News

Mylan offers $28 billion for Perrigo

April 9, 2015
Life sciences
Mylan has made an offer to buy Dublin, Ireland-based Perrigo for more than $28 billion, as the current acquisitions trend in pharma continues at pace.
 
The company said it would pay $205 in a combination of cash and Mylan stock for each Perrigo share, which represents a greater than 25% premium to the latter’s stock price as of April 3, 2015.
 
According to Mylan, the marriage of these “highly complementary businesses” would create “a diversified, global pharmaceutical leader with an unmatched commercial and operating platform and a unique, one-of-a-kind profile”. 
 
In a letter to Perrigo’s chairman, Mylan chief Robert Coury noted that the proposed transaction “makes compelling strategic sense” and would result in a combined company with “a very strong financial profile”, with annual sales of more than $15 billion.
 
Perrigo confirmed receipt of the offer, and noted that its board will now meet to discuss the proposal.
 
Mylan’s move comes just months after it relocated its headquarters from the US to The Netherlands as part of its purchase of Abbott’s main branded generics business, thereby considerably cutting its tax bill.
 
By Selina McKee
 
Source: Pharma Times
 

comments closed

Related News

May 4, 2024

Novartis acquires Mariana in $1.75bn deal to strengthen radioligand portfolio

Life sciences

Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.

May 4, 2024

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Life sciences

The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.

May 4, 2024

Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn

Life sciences

Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.

How can we help you?

We're easy to reach